ArticleBiomolecules2026
A Node-Adaptive Feature Fusion Network for Drug-Target Interaction Prediction Based on Multi-View Graphs.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Existing drug-target interaction (DTI) prediction methods still face challenges caused by sparse interaction data, complex multi-source relationships, and imbalanced information contributions among different nodes. In this study, we propose NAFF-DTI, a node-level adaptive feature fusion network based on multi-view graphs. The model uniformly represents drug similarity, target similarity, and known drug-target interactions as multiple relational views, and learns node representations through graph encoding and cross-view representation learning. To more effectively utilize heterogeneous relational information, NAFF-DTI introduces cross-view feature discrepancy modeling and a node-level adaptive fusion mechanism to dynamically adjust the contribution of different views according to node structural characteristics. Experimental results show that NAFF-DTI achieves the best AUC and AUPR on all five benchmark datasets. Compared with the strongest baseline for each dataset and metric, NAFF-DTI achieves average relative improvements of 3.81% in AUC and 3.23% in AUPR. It can also improve the utilization of multi-source information, maintain relatively stable prediction under different data distributions, and prioritize biologically plausible candidate drug-target associations from the unannotated candidate space. These results indicate that NAFF-DTI can provide computational support for DTI candidate prioritization and repurposing-oriented hypothesis generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.